In the last trading session, 1.76 million Xeris Biopharma Holdings Inc (NASDAQ:XERS) shares changed hands as the company’s beta touched 1.85. With the company’s per share price at $2.79 changed hands at -$0.06 or -2.11% during last session, the market valuation stood at $415.71M. XERS’s last price was a discount, traded about -16.85% off its 52-week high of $3.26. The share price had its 52-week low at $1.46, which suggests the last value was 47.67% up since then. When we look at Xeris Biopharma Holdings Inc’s average trading volume, we note the 10-day average is 1.55 million shares, with the 3-month average coming to 1.52 million.
Analysts gave the Xeris Biopharma Holdings Inc (XERS) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.00. If we narrow down to specifics, the data shows that 0 out of 3 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended XERS as a Hold, 3 felt it is a Buy and 0 rated the stock as Underweight. Xeris Biopharma Holdings Inc’s EPS for the current quarter is expected to be -0.09.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Xeris Biopharma Holdings Inc (NASDAQ:XERS) trade information
Instantly XERS was in red as seen at the end of in last trading. With action -1.06%, the performance over the past five days has been red. The company’s shares are showing year-to-date upside of 18.72%, with the 5-day performance at -1.06% in the red. However, in the 30-day time frame, Xeris Biopharma Holdings Inc (NASDAQ:XERS) is -0.71% down. Looking at the short shares, we see there were 11.0 million shares sold at short interest cover period of 6.34 days.
The consensus price target for the stock as assigned by Wall Street analysts is 4.75, meaning bulls need an upside of 41.26% from its current market value. According to analyst projections, XERS’s forecast low is 3 with 6.5 as the target high. To hit the forecast high, the stock’s price needs a -132.97% plunge from its current level, while the stock would need to soar -7.53% for it to hit the projected low.
Xeris Biopharma Holdings Inc (XERS) estimates and forecasts
Data shows that the Xeris Biopharma Holdings Inc share is performing relatively much not better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot 33.49% over the past 6 months, a 11.11% in annual growth rate that is considerably lower than the industry average of 20.00%. Year-over-year growth is forecast to reach 18.00% up from the last financial year.
Consensus estimates given by 6 financial analysts project the company’s revenue in the current quarter to hit an average of 51.43M. 6 analysts are of the opinion that Xeris Biopharma Holdings Inc’s revenue for the current quarter will be 53.27M. The company’s revenue for the corresponding quarters a year ago was 48.32M and 44.39M respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at 6.40%. The estimates for the next quarter sales put growth at 20.00%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 38.13%. The 2024 estimates are for Xeris Biopharma Holdings Inc earnings to increase by 14.81%.
XERS Dividends
Xeris Biopharma Holdings Inc is expected to release its next quarterly earnings report in November.
Xeris Biopharma Holdings Inc (NASDAQ:XERS)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 3.91% of Xeris Biopharma Holdings Inc shares while 41.68% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 43.37%. There are 41.68% institutions holding the Xeris Biopharma Holdings Inc stock share, with BLACKROCK INC. the top institutional holder. As of 2024-06-30, the company held 7.3531% of the shares, roughly 10.33 million XERS shares worth $23.25 million.
VANGUARD GROUP INC holds the second largest percentage of outstanding shares, with 5.4492% or 7.66 million shares worth $17.23 million as of 2024-06-30.
